用去纤维钠可能产生什么不良现象？

(Defibrinoside) is a single-stranded oligonucleotide mixture. Preclinical tests have proven that it has anti-thrombotic, fibrinolytic, anti-ischemic, and anti-infective effects in vivo and in vitro.

As an injectable drug, patients must strictly follow the prescribed usage method. For the treatment of children and adults, the dose of defibrotide is based on body weight. The recommended dose is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The minimum period of administration of defibrinated sodium is 21 days. If signs and symptoms of HVOD have not resolved after 21 days, continue defibrination until resolution of HVOD or up to a maximum of 60 days.

What are the possible adverse effects of using defibrinated sodium?

The most common (incidence ≥10% and independent causal relationship) adverse effects of defibrotide therapy are hypotension, diarrhea, vomiting, nausea, and epistaxis. The incidence of grade 3-4 reactions related to defibrotide sodium was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients stopped treatment due to side effects. In other words, the adverse reactions of defibrinated sodium are usually mild, and patients do not need to worry too much.

A phase 3 randomized controlled trial of defibrinated sodium for the prevention of hepatic VOD in pediatric transplant patients has also been completed. Defibrotide sodium has been generally well tolerated; the most common adverse events observed during premarketing use to treat hepatic VOD were bleeding, hypotension, and coagulopathy.

Patients should do regular physical examinations during the medication, maintain a happy mood, and enhance the body's immunity, which will greatly reduce the chance of side effects. If serious side effects occur while using defibrinated sodium, the medication should be discontinued and seek medical attention as soon as possible. Do not blindly change the dosage.

Recommended related hot articles: /newsDetail/71787.html